Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 50 条

[11] ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK plus NSCLC
Yang, J. C-H.
Liu, G.
Lu, S.
He, J.
Burotto, M.
Vincent, S.
Yin, J.
Ma, X.
Popat, S.
ANNALS OF ONCOLOGY, 2022, 33 : S1564 - S1564
[12] Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial
Kim, D.
Huber, R.
Ahn, M.
Langer, C.
Tiseo, M.
West, H.
Groen, H.
Reckamp, K.
Hochmair, M.
Leighl, N.
Hansen, K. H.
Gettinger, S.
Paz-Ares Rodriguez, L.
Kim, E.
Smit, E.
Kim, S.
Reichmann, W.
Kerstein, D.
Camidge, D. R.
LUNG CANCER, 2019, 127 : S30 - S31
[13] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
Kim, Dong-Wan
Tiseo, Marcello
Ahn, Myung-Ju
Reckam, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Lange, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William G.
Kerstein, David
Haluska, Frank G.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[14] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
Griesinger, F.
Camidge, D. R.
Kim, H. R.
Ahn, M. -J.
Yang, J. C. -H.
Han, J. -Y.
Lee, J. -S.
Hochmair, M.
Li, J. Y. -C.
Chang, G. -C.
Lee, K. H.
Gridelli, C.
Delmonte, A.
Campelo, Garcia M. R.
Kim, D. -W.
Bearz, A.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
[15] Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
Lee, D. H.
Kim, D-W.
Camidge, D. R.
Langer, C. J.
Huber, R. M.
Tiseo, M.
West, H. L.
Groen, H. J. M.
Reckamp, K. L.
Hochmair, M. J.
Leighl, N. B.
Hansen, K. H.
Gettinger, S. N.
Paz-Ares, L.
Kim, E. S.
Smit, E. F.
Kim, S-W.
Ni, Q.
Zhang, P.
Ahn, M-J.
ANNALS OF ONCOLOGY, 2019, 30 : 634 - +
[16] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
Califano, R.
Camidge, D.
Kim, H. -R.
Ahn, M. -J.
Yang, J.
Han, J. -Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D. -W.
Griesinger, F.
Felip, E.
Spira, A.
Gettinger, S.
Tiseo, M.
Ni, Q.
Zhang, P.
Popat, S.
LUNG CANCER, 2020, 139 : S59 - S60
[17] Brigatinib vs crizotinib in ALK TKI-naive ALK plus NSCLC: final results from ALTA-1L
Popat, Sanjay
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James
Han, Ji-Youn
Hochmair, Maximilian
Lee, Ki Hyeong
Delmonte, Angelo
Garcia Campelo, Maria
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander
Gettinger, Scott
Tiseo, Marcello
Lin, Huamao
Liu, Yuyin
Vranceanu, Florin
Camidge, D.
LUNG CANCER, 2022, 165 : S27 - S28
[18] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials
Huber, R.
Gettinger, S.
Kim, D. -W
Bazhenova, L.
Hansen, K.
Tiseo, M.
Langer, C.
Paz-Ares Rodriguez, L.
West, H.
Reckamp, K.
Weiss, G.
Smit, E.
Hochmair, M.
Kim, S. -W
Ahn, M. -J
Kim, E.
Groen, H.
Pye, J.
Vranceanu, F.
Camidge, D. R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 4 - 5
[19] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Camidge, R.
Kim, H. R.
Ahn, M.
Yang, J. C.
Han, J.
Lee, J.
Hochmair, M.
Li, J. Y.
Chang, G.
Lee, K.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
[20] Brigatinib in Japanese patients (pts) with ALK plus NSCLC: Final results from the phase 2 J-ALTA trial.
Zhang, Pingkuan
Kumagai, Toru
Yoshida, Tatsuya
Nishio, Makoto
Toyozawa, Ryo
Seto, Takashi
Nakagawa, Kazuhiko
Ohe, Yuichiro
Yamamoto, Nobuyuki
Kudou, Kentarou
Asato, Takayuki
Goto, Koichi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →